Screener
Sarepta Therapeutics, Inc. SRPT Interest expense on dilutive Convertible Notes
Interest expense on dilutive Convertible Notes at other companies
Other financials
Where this comes from
Reported directly by Sarepta Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InterestOnConvertibleDebtNetOfTax.
The source filing: Sarepta Therapeutics, Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 4:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-335003
FAQ
- What is Sarepta Therapeutics, Inc.'s interest expense on dilutive convertible notes?
- Sarepta Therapeutics, Inc. (SRPT) reported interest expense on dilutive convertible notes of $0 in Q2 2026.
- What does interest expense on dilutive convertible notes mean?
- Interest expense on dilutive Convertible Notes as reported by Sarepta Therapeutics,, Inc. Common Stock.
Ask your AI about Sarepta Therapeutics, Inc.'s interest expense on dilutive convertible notes.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude